These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 8000725)

  • 21. Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin.
    Oge A; Alkiş N; Oge O; Kartum A
    J Chemother; 2000 Feb; 12(1):105-8. PubMed ID: 10768522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review of experience with ondansetron and granisetron.
    Aapro MS
    Ann Oncol; 1993; 4 Suppl 3():9-14. PubMed ID: 8395875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis.
    Jordan K; Hinke A; Grothey A; Schmoll HJ
    Support Care Cancer; 2005 Jan; 13(1):26-31. PubMed ID: 15668744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5-HT3 receptor antagonists: differences and similarities.
    Roila F; Ballatori E; Tonato M; Del Favero A
    Eur J Cancer; 1997 Aug; 33(9):1364-70. PubMed ID: 9337675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomised double blind crossover study comparing ondansetron, granisetron and tropisetron. A cost-benefit analysis.
    Barrajon E; de las Peñas R
    Support Care Cancer; 2000 Jul; 8(4):323-33. PubMed ID: 10923774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade?
    Blower P; Aapro M
    Br J Cancer; 2002 May; 86(10):1662-3; author reply 1664. PubMed ID: 12085221
    [No Abstract]   [Full Text] [Related]  

  • 27. A risk-benefit assessment of serotonin 5-HT3 receptor antagonists in antineoplastic therapy-induced emesis.
    Perez EA
    Drug Saf; 1998 Jan; 18(1):43-56. PubMed ID: 9466087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists.
    Babaoglu MO; Bayar B; Aynacioglu AS; Kerb R; Abali H; Celik I; Bozkurt A
    Clin Pharmacol Ther; 2005 Dec; 78(6):619-26. PubMed ID: 16338277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.
    Plosker GL; Benfield P
    Pharmacoeconomics; 1996 Apr; 9(4):357-74. PubMed ID: 10160110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serotonin antagonists: a new class of antiemetic agents.
    Hesketh PJ; Gandara DR
    J Natl Cancer Inst; 1991 May; 83(9):613-20. PubMed ID: 1850806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. '... setron': are 5-HT3 receptor antagonists different?
    Aapro MS
    Eur J Cancer; 1993; 29A(12):1655. PubMed ID: 8398287
    [No Abstract]   [Full Text] [Related]  

  • 32. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Possible involvement of 5-HT4 receptors, in addition to 5-HT3 receptors, in the emesis induced by high-dose cisplatin in Suncus murinus.
    Horikoshi K; Yokoyama T; Kishibayashi N; Ohmori K; Ishii A; Karasawa A
    Jpn J Pharmacol; 2001 Jan; 85(1):70-4. PubMed ID: 11243577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Serotonin and anticancer drug-induced emesis].
    Minami M; Endo T; Hamaue N; Hirafuji M
    Yakugaku Zasshi; 2004 Aug; 124(8):491-507. PubMed ID: 15297719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
    Stiakaki E; Savvas S; Lydaki E; Bolonaki I; Kouvidi E; Dimitriou H; Kambourakis A; Kalmanti M
    Pediatr Hematol Oncol; 1999; 16(2):101-8. PubMed ID: 10100270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A randomized double-blind study of prevention of postoperative nausea and vomiting with ondansetron, tropisetron, or granisetron in patients undergoing general anesthesia].
    Quan X; Ye TH; Zhu B
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Feb; 29(1):107-10. PubMed ID: 17380679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy of 5-HT3 receptor antagonists for the prevention of postoperative nausea and vomiting after craniotomy: a meta-analysis.
    Neufeld SM; Newburn-Cook CV
    J Neurosurg Anesthesiol; 2007 Jan; 19(1):10-7. PubMed ID: 17198095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials.
    del Giglio A; Soares HP; Caparroz C; Castro PC
    Cancer; 2000 Dec; 89(11):2301-8. PubMed ID: 11147601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancing the effectiveness of the specific serotonin antagonists. Combination antiemetic therapy with dexamethasone.
    Kris MG; Baltzer L; Pisters KM; Tyson LB
    Cancer; 1993 Dec; 72(11 Suppl):3436-42. PubMed ID: 8242576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
    Madej G; Krzakowski M; Pawinski A; Lasota W; Rogowski W; Skoneczna I
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):3-6. PubMed ID: 9113119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.